Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

Other authors

Institut Català de la Salut

[Genescà E, González-Gil C, Fuster-Tormo F] Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain. [Morgades M] Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain. Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Spain. [Haferlach C, Meggendorfer M] MLL Munich Leukemia Laboratory, Munich, Germany. [Barba P] Servei d’Hematologia Clínica, Vall d'Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2022-06-14T07:29:05Z

2022-06-14T07:29:05Z

2021-10



Abstract

Cytogenetics; Prognosis; Therapy


Citogenética; Pronóstico; Terapia


Citogenètica; Pronòstic; Teràpia


The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.


This project was supported by the AECC (GC16173697BIGA); ISCIII (PI19/01828) co-funded by ERDF/ESF "A way to make Europe"/"Investing in your future", CERCA/Generalitat de Catalunya SGR 2017 288 (GRC)/ “La Caixa” P. Barba was supported by the Instituto de Salud Carlos III FIS16/01433 and PERIS 2018-2020 from Generalitat de Catalunya (BDNS357800).

Document Type

Article


Published version

Language

English

Publisher

Elsevier

Related items

Leukemia Research;109

https://doi.org/10.1016/j.leukres.2021.106612

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)